首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   125993篇
  免费   11731篇
  国内免费   8859篇
耳鼻咽喉   1042篇
儿科学   1537篇
妇产科学   1325篇
基础医学   12895篇
口腔科学   2312篇
临床医学   16679篇
内科学   16798篇
皮肤病学   1211篇
神经病学   5508篇
特种医学   4839篇
外国民族医学   61篇
外科学   11789篇
综合类   25685篇
现状与发展   42篇
一般理论   3篇
预防医学   9669篇
眼科学   2878篇
药学   13945篇
  113篇
中国医学   8709篇
肿瘤学   9543篇
  2024年   502篇
  2023年   2176篇
  2022年   5075篇
  2021年   6116篇
  2020年   4788篇
  2019年   3724篇
  2018年   3901篇
  2017年   3891篇
  2016年   3450篇
  2015年   5570篇
  2014年   6782篇
  2013年   6569篇
  2012年   9817篇
  2011年   10688篇
  2010年   7532篇
  2009年   6197篇
  2008年   7362篇
  2007年   7449篇
  2006年   7020篇
  2005年   6682篇
  2004年   4443篇
  2003年   3870篇
  2002年   3171篇
  2001年   2825篇
  2000年   2835篇
  1999年   2777篇
  1998年   1723篇
  1997年   1638篇
  1996年   1260篇
  1995年   1095篇
  1994年   917篇
  1993年   626篇
  1992年   725篇
  1991年   624篇
  1990年   573篇
  1989年   490篇
  1988年   406篇
  1987年   368篇
  1986年   261篇
  1985年   202篇
  1984年   100篇
  1983年   79篇
  1982年   49篇
  1981年   47篇
  1980年   29篇
  1979年   31篇
  1964年   17篇
  1963年   14篇
  1958年   14篇
  1957年   14篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
Major ursodeoxycholic acid (UDCA)-based therapies for primary biliary cirrhosis (PBC) include UDCA only, or combined with either methotrexate (MTX), corticosteroids (COT), colchicine (COC), or bezafibrate (BEF). As the optimum treatment regimen is unclear and warrants exploration, we aimed to compare these therapies in terms of patient mortality or liver transplantation (MOLT) and adverse events (AE).PubMed, the Cochrane Library, and Scopus were searched for randomized controlled trials up to August 31, 2014. We estimated the hazard ratios (HRs) for MOLT and odds ratios (ORs) for AE. A sensitivity analysis based on the dose of UDCA was also executed.Thirty-one eligible articles were included. Compared with COT plus UDCA, UDCA (HR 0.38, 95% confidence interval [CI] 0.09–1.39), BEF plus UDCA (HR 0.29, 95% CI 0.02–4.83), COC plus UDCA (HR 0.39, 95% CI 0.07–2.25), MTX plus UDCA (HR 0.28, 95% CI 0.05–1.63), or OBS (HR 0.49, 95% CI 0.11–2.01) all provided an increased risk of MOLT. With respect to drug AE profile, although not differing appreciably, BEF plus UDCA was associated with more AEs compared with UDCA (OR 3.16, 95% CI 0.59–20.67), COT plus UDCA (OR 2.27, 95% CI 0.15–33.36), COC plus UDCA (OR 1.00, 95% CI 0.09–12.16), MTX plus UDCA (OR 2.03, 95% CI 0.23–17.82), or OBS (OR 3.00, 95% CI 0.53–20.75). The results of sensitivity analyses were highly consistent with previous analyses.COT plus UDCA was the optimal UDCA-based regimen for both MOLT and AEs. BEF plus UDCA was most likely to cause AEs, whereas monotherapy with UDCA and coadministriation of COT plus UDCA appeared to be associated with the fewest AEs for PBC treatment.  相似文献   
4.
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples.  相似文献   
5.
罗田  程晓萍  熊燕 《卫生研究》2015,(2):252-256
目的探讨深圳市3家制造企业新招90后产线员工心理弹性、应对方式和心理健康间是否存在某种关系。方法在深圳市3家制造企业选取入职一周的新招90后产线员工,以其入职日期为单位进行整群抽样。应用心理弹性量表CDRISC、简易应对方式问卷SCSQ以及一般健康问卷GHQ-20三个量表分别测量其心理弹性、应对方式以及心理健康,并利用结构方程模型软件Amos 17.0进行路径分析。结果心理弹性与心理健康呈正相关关系(P<0.01);心理弹性和心理健康与积极应对呈正相关关系(P<0.01);心理弹性和心理健康与消极应对呈负相关关系(P<0.01);结构方程模型结果表明:心理弹性既可以直接影响心理健康,又可以通过积极应对和消极应对的中介作用间接影响心理健康。结论深圳市制造企业新招产线员工的心理弹性、应对方式与心理健康间存在线性相关关系,且心理弹性通过积极应对和消极应对对心理健康起着部分间接的作用。  相似文献   
6.
7.
Melatonin induces apoptosis in many different cancer cell lines, including colorectal cancer. However, the precise mechanisms involved remain largely unresolved. In this study, we provide evidence to reveal a new mechanism by which melatonin induces apoptosis of colorectal cancer LoVo cells. Melatonin at pharmacological concentrations significantly suppressed cell proliferation and induced apoptosis in a dose‐dependent manner. The observed apoptosis was accompanied by the melatonin‐induced dephosphorylation and nuclear import of histone deacetylase 4 (HDAC4). Pretreatment with a HDAC4‐specific siRNA effectively attenuated the melatonin‐induced apoptosis, indicating that nuclear localization of HDAC4 is required for melatonin‐induced apoptosis. Moreover, constitutively active Ca2+/calmodulin‐dependent protein kinase II alpha (CaMKIIα) abrogated the melatonin‐induced HDAC4 nuclear import and apoptosis of LoVo cells. Furthermore, melatonin decreased H3 acetylation on bcl‐2 promoter, leading to a reduction of bcl‐2 expression, whereas constitutively active CaMKIIα(T286D) or HDAC4‐specific siRNA abrogated the effect of melatonin. In conclusion, the present study provides evidence that melatonin‐induced apoptosis in colorectal cancer LoVo cells largely depends on the nuclear import of HDAC4 and subsequent H3 deacetylation via the inactivation of CaMKIIα.  相似文献   
8.
9.
10.
目的分析2014-2018年黄山市淋病的流行特征,为全市的淋病防控工作提供科学依据。方法通过中国疾病预防控制信息系统收集黄山市2014—2018年的淋病数据、人口数据,进行统计分析。结果2014—2018年黄山市累计报告淋病病例761例,年均发病率为11.09/10万,年均增长率为29.14%,发病率呈逐年上升趋势(χ^2趋势=112.29,P<0.05)。淋病的人群分布中,男女报告病例数之比为13.63:1,男女发病率有统计学差异(χ^2=113.18,P<0.05);15~49岁年龄组病例数最多,占85.94%,职业以农民最多,占44.81%;以屯溪区、歙县报告病例数较多,分别占37.45%、23.26%。结论2014—2018年黄山市淋病发病率呈上升趋势,淋病防控形势严峻,需进一步完善各项防控措施。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号